TickerTalks
Browse all tickers →
TickerTalks›$STRO
STSTRO

Sutro Biopharma, Inc.

$STRO·$234M·Biotechnology·Healthcare
$20.45-4.0%YTD+123.2%1Y+128.5%
Mentions · last 7 days
2026-08-19: 2 posts2026-08-20: 1 posts2026-08-21: 1 posts2026-08-22: 1 posts15+7%
Price updated 5h ago·X counts updated 6d ago
STSTRO
$STROSutro Biopharma, Inc.
$20.45-4.04%15 posts+7%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Today's AI verdict on what's driving $STRO, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Hinges on a big eventAcceleratingAI verdict · as of 2026-08-21

The move is getting stronger, with heavier trading behind it.

ADC clinical-stage biotech more than doubled year-to-date — STRO-004 Phase 1 data is the whole story.

Sutro Biopharma is a clinical-stage biotech developing antibody-drug conjugates (ADCs) and immunology programs — the specific approach that made Enhertu (Daiichi/AZ) a multi-billion-dollar franchise. The equity story is a portfolio of Phase 1-2 assets with STRO-004 currently in the spotlight.

  • Q1 revenue was $14.5M (down 16% year-on-year), mostly collaboration income — the equity value is not tied to current P&L; the whole bet is on ADC pipeline data.
  • Stock is +123% year-to-date and +145% over 12 months but sits at the 38th percentile of its 52-week range — the run has been off a low base and the recent Q2 print produced a pullback despite the run.
  • Analyst 2026 revenue estimate is $44.6M, 2027 drops to $34.4M — the estimated revenue path implies a specific pipeline commercialization timing that is still highly uncertain; the equity value is essentially all optionality.
  • Trades at ~2.5x TTM sales but the enterprise value is negative on the balance-sheet math (net cash exceeds market cap) — a genuinely unusual setup that means downside is somewhat buffered by cash.

The next test is any STRO-004 Phase 1 dose-escalation data update — that specific readout decides whether the equity extends the accelerating trajectory or gives back the 2x move. What sustains the acceleration is a positive Phase 1 signal or a partnership announcement; what breaks it is a safety signal or an FDA design objection on STRO-004 next steps.

What to watch: Any STRO-004 Phase 1 data cut or FDA interaction. Nov 5 Q3 earnings will carry pipeline updates and cash-runway detail — the negative EV setup means runway is not the constraint yet.

On the calendar: 2026-11-05 — Q3 earnings

Read the AI verdict + X sentiment for $STRO

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Develops antibody-drug conjugates using cell-free protein synthesis platform targeting oncology and inflammatory diseases.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $STRO.

Biotechnology · Healthcare

No material change from last week — ADA conference oral formulation competition is bifurcating biotech multiples between GLP-1 platform holders and precision oncology innovators.

What this means for $STRO

Partial — Develops antibody-drug conjugates using cell-free protein synthesis platform targeting oncology and inflammatory diseases; partial earnings exposure to biotechnology demand dynamics through its product portfolio.

Top industry ETF

$IBBiShares Biotechnology ETF
+12.1%YTD
+51.2%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-0.0How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-64.3%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
-116%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-60.3%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
2.5Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
193%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
98.7%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
-0.2Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Aug 12, 2026$-2.33$-2.19-6.4%
Q1 2026May 14, 2026$-2.94$-2.32-26.7%
Q4 2025Mar 23, 2026$-5.29$-8.16+35.2%
Q3 2025Nov 6, 2025$-6.70$-3.94-69.9%
Next earningsThu, Nov 5·consensus EPS $-1.66

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$14.5M-16.5%91.2%-204%$-294.17$-42.3M
Q4 FY25$11.6M-21.4%100%-289%$-5.45$-26.6M
Q3 FY25$9.7M+13.8%100%-500%$-6.70$-38.4M
Q2 FY25$63.7M+148.0%100%-5.2%$-1.40$-44.8M

Forward consensus

5-year forecast · up to 9 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$44.6M$27.2M – $66.1M-$8.53-$9.65 – -$6.929
FY27$34.4M$1.9M – $62.6M-$7.39-$10.52 – -$4.809
FY28$42.3M$14.4M – $67.9M-$7.24-$10.02 – -$4.089
FY29$41.7M$14.2M – $67.0M-$6.66-$11.93 – -$0.954
FY30$69.0M$23.5M – $111.0M-$6.07-$10.87 – -$0.874

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.7×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.39%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-17.1%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.-1.8%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatTiny float · 6.8M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today3.1% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β1.515-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

No open-market buys or sells in the last 180 days.

+ 23 other (12 awards · 6 exempts · 5 inkinds) in window

See when $STRO insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KPress release / Reg FDAug 128-K — Item 2.02: Earnings release · Item 7.01: Press release / Reg FD
AI summary

Sutro Biopharma, Inc. reported Q2 2026 financial results for the quarter ended June 30, 2026, and simultaneously released an updated corporate presentation via its investor relations website. The South San Francisco-based biotech focuses on antibody-drug conjugate and immunology programs. Detailed financials were furnished as exhibits. The concurrent corporate presentation update suggests active investor communications around pipeline milestones.

8-KShareholder voteJun 88-K — Item 5.07: Shareholder vote
AI summary

Sutro Biopharma, Inc. held its 2026 Annual Meeting on June 5, 2026. Shareholders elected three Class II directors (Jane Chung, Connie Matsui, James Panek) to three-year terms expiring in 2029 — all passed, with Chung receiving the strongest support (~11.4M votes for). Ernst & Young LLP was ratified as independent auditor for fiscal year 2026 with near-unanimous approval (13.9M for, 501 against). The advisory say-on-pay vote also passed (~11.3M for vs. 22K against). This is routine annual governance with no contested matters or adverse outcomes.

S-3Shelf registrationMar 23S-3
AI summary

STRO filed a S-3 shelf registration statement dated 2026-03-23. The shelf provides capacity to issue equity or debt as market conditions allow. No immediate capital raise is triggered; watch for prospectus supplements disclosing actual transactions.

8-KAgreement terminatedMar 238-K — Item 1.02: Agreement terminated · Item 2.02: Earnings release
AI summary

STRO reported period ending 2026-03-23 financial results (8-K Item 2.02). Investors should review the full earnings press release and any management guidance for forward outlook.

+ 20 other (9 13Gs · 2 10-Qs · 2 proxys · 1 earnings 8-K) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Why is Sutro Biopharma Stock Falling On Wednesday?benzinga.com·17d agoSutro Biopharma Reports Second Quarter 2026 Financial Results and Provides Early Update on STRO-004 Phase 1 Studyglobenewswire.com·17d agoHere Are Friday’s Top Wall Street Analyst Research Calls: Baker Hughes, Etsy, HubSpot, Instacart, JetBlue, Roku, SpaceX, Tower Semiconductor, Trade Desk, and More247wallst.com·22d agoAffinity Asset Advisors LLC Grows Stock Holdings in Sutro Biopharma, Inc. $STROdefenseworld.net·35d ago

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$MRNA$ALT$AURA$IOVA$NWBO$SLS$AMLX$ABCL
Voices on X · last 7 days

No standout posts about $STRO on X in the last 7 days.

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport